Æó¼â¼º ¼ö¸é¹«È£ÈíÀÇ Ä¡·á¸¦ À§ÇÑ À̽ÄÇü Ä¡·á±â: ¼³ÇϽŰæ ÀÚ±Ø Ä¡·á
An Implantable Device for Treatment of Obstructive Sleep Apnea: Hypoglossal Nerve Stimulation Therapy
´ëÇÑÀ̺ñÀÎÈÄ-µÎ°æºÎ¿Ü°úÇÐȸÁö 2015³â 58±Ç 5È£ p.299 ~ p.304
±è»ó¿í(Kim Sang-Wook) - °æ»ó´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø À̺ñÀÎÈÄ°úÇб³½Ç
Abstract
Among current treatment options for obstructive sleep apnea (OSA) including surgeries and oral appliances, positive airway pressure (PAP) is accepted as a standard modality, particularly for moderate to severe OSA patients. Because long-term compliance for PAP is less than 50%, however, strong demands for a novel therapy have existed. Based on the findings that electromyographic activities of pharyngeal dilator muscles are significantly decreased in OSA patients during sleep, researches on hypoglossal nerve stimulation (HGNS) have been conducted. Therapeutic effects of HGNS on OSA have been proven through a series of clinical trials, and the American Food and Drug Administration recently approved its application on moderate to severe OSA patients who failed or are intolerant to PAP treatment. Given recent advances in HGNS therapy, it would be timely to review the history of HGNS and discuss its clinical implications.
Å°¿öµå
WordsZZElectric stimulation therapy, Hypoglossal nerve, Implantable neurostimulators, Sleep apnea, obstructive, Tongue
KMID :
0361020150580050299
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Therapeutic effects of HGNS on OSA have been proven through a series of clinical trials, and the American Food and Drug Administration recently approved its application on moderate to severe OSA patients who failed or are intolerant to PAP treatment.